Aptuit makes two additions to Executive Leadership team

New CFO and VP of Sales and Business Development

Aptuit, a US supplier of drug discovery and development services, has appointed two new members to its Executive Leadership team.

Kurt Dinkelacker has been named Executive Vice President and Chief Financial Officer and Kevin Duffield has been promoted to Vice President, Sales and Business Development.

Dinkelacker reports directly to Stuart Needleman, Aptuit’s President and COO. Previously, he was an Executive Vice President and CFO at Retrievex. Before that, he held leadership positions at Financing Alternatives, TeleSpectrum Worldwide and IKON Office Solutions.

Duffield takes on new responsibilities as Aptuit’s Vice President of Sales and Business Development. He will be handling global sales and marketing, also reporting directly to Needleman. He has more than 25 years of experience in pharmaceutical contract manufacturing services. He has held several leadership positions in sales, business development, and operations of cGMP development and manufacturing facilities. Before he joined Aptuit, he worked for Eastman Fine Chemicals, ChiRex and NovaSep.

You may also like

Media

Evotec to acquire Aptuit, expanding leadership in external innovation

Evotec and Aptuit have entered into a definitive agreement, Evotec will acquire Aptuit for US$ 300 million
Research & Development

Aptuit and Chiesi initiate discovery project to identify compounds to treat idiopathic pulmonary fibrosis

Both parties will contribute scientifically, with Aptuit providing integrated early discovery capabilities, including medicinal chemistry and pharmacology, as well as drug metabolism and pharmacokinetics, to identify promising compounds for further preclinical development
Research & Development

Aptuit and Dimension Therapeutics partner to advance AAV gene therapies

Activities have commenced for three gene therapy programmes in rare disease indications
Research & Development

Aptuit acquires Kuecept

Expanding capabilities in formulation development to include specialist pre-formulation, formulation prototyping and formulation development services
Research & Development

Aptuit announces acquisition of Exquiron Biotech

Company expands capabilities in discovery to include high throughput screening and other early discovery services
Research & Development

Aptuit to invest US$16m in capacity and capabilities

Will also hire 90 additional scientists during 2016
Manufacturing

Aptuit invests in expanding manufacturing scale and adds new formulation capabilities

Offers manufacturing to Phase III and commercial scale
Subscribe now